During the past two decades, the clinical use of biopharmaceutical products has markedly
increased because of their obvious advantages over conventional small-molecule drug …

This review highlights the recent developments in the area of nanocarrier-based mucosal
delivery of therapeutic biomolecules and antigens. Macromolecular drugs have the unique …

Macromolecular therapeutics of biological origin, also known as biologics, have become
one of the fastest-growing classes of drugs for management of a range of chronic and acute …

Many pharmaceuticals on the market suffer from two significant limitations to their activity:
lack of specificity toward the pathological site and poor aqueous solubility. Both factors …

Nanobiotechnology, involving biological systems manufactured at the molecular level, is a
multidisciplinary field that has fostered the development of nanoscaled pharmaceutical …

Over the years, a plethora of materials–natural and synthetic–have been engineered at a
nanoscopic level and explored for drug delivery. Nanocarriers based on such materials …

Poor bioavailability and poor pharmacokinetic characteristics are some of the leading
causes of drug development failure. Therefore, poorly-soluble drugs, fragile proteins or …

Nanotechnology has ultimately come into the domain of drug delivery. Nanosystems for
delivery of drugs are promptly emerging science utilizing different nanoparticles as carriers …

Background: Nanocarriers have been a part of drug delivery for some decades now. Due to
the enormous advantages offered by them, they are replacing the conventionally available …

Systemic drug delivery methods such as oral or parenteral administration of free drugs
possess relatively low treatment efficiency and marked adverse side effects. The use of …